CompletedPhase 3NCT04650399

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Studying Chikungunya

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Butantan Institute
Principal Investigator: Fernanda Boulos, MD, MSc
Butantan Institute
Intervention: Active(biological)
Enrollment: 750 enrolled
Eligibility: 12-17 years · All sexes
Timeline: 2022 – 2024

Study locations (10)

CECOR - Centro Oncológico de Roraima, Boa Vista, Acre, Brazil
Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus, Amazonas, Brazil
Núcleo de Medicina Tropical - Universidade Federal do Ceará, Fortaleza, Ceará, Brazil
Associação Obras Sociais Irmã Dulce / Centro de Pesquisa Clínica - CPEC, Salvador, Estado de Bahia, Brazil
Centro de Pesquisa e Desenvolvimento de Fármacos (CPDF) - Universidade Federal de Minas Gerais, Instituto de Ciências Biológicas, Belo Horizonte, Minas Gerais, Brazil
Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, Brazil
Centro de Pesquisas Clínicas Universidade Federal Sergipe, Aracaju, Sergipe, Brazil
Faculdade de Medicina de São José do Rio Preto - FAMERP, São José do Rio Preto, São Paulo, Brazil
Centro de Pesquisa Clínica da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul - UFMS, Campo Grande, Brazil
Centro de Estudos do Instituto de Infectologia Emílio Ribas, São Paulo, Brazil

Collaborators

Valneva Austria GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04650399 on ClinicalTrials.gov

Other trials for Chikungunya

Additional recruiting or active studies for the same condition.

See all trials for Chikungunya →

← Back to all trials